bpc 157 enhanced athlete bpc 157 enhanced athlete BPC-157 Therapy in San Antonio BPC 157 (Body Protection Compound-157)

This medicine is not recommended for use in pregnant women unless necessary

The pivotal trial supporting its 2010 FDA approval enrolled 816 HIV-infected adults with clinically defined lipodystrophy, and Phase 3 data documented visceral fat reductions of roughly 15-18% over 26 weeks of treatment a result robust enough to clear FDA review for a defined medical indication

The evening dose works best if administered at least two hours after your last meal, ensuring reduced insulin interference

(Excluding IV Therapy)

Reported, but not confirmed Important limits Food effects and human oral tolerability have not been studied